Clinical trials: SARS-CoV-2 Virus Infection
COVID-19
Estimated Vaccine Effectiveness and Durability of Pfizer/BioNTech 2024-2025 COVID-19 Vaccine
This study is a retrospective case control analysis on the real-world effectiveness of the Pfizer-BioNTech BNT162b2 vaccine (2024-2025 formulation) against symptomatic SARS-CoV-2 infection among CVS MinuteClinic patients testing…
- Trial name
- C4591068 (NCT06703190)
- Testing
- Pfizer-BioNTech BNT162b2 COVID-19 Vaccinated, Not vaccinated with 2024-2025 formulated COVID-19 vaccine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Pfizer
Covid19
Phase III Clinical Trial of CinnaGen COVID-19 Vaccine (SpikoGen)
This is a phase III, randomized, two-armed, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of a candidate adjuvanted recombinant SARS-CoV-2 spike (S) protein subunit vaccine (SpikoGen)…
- Trial name
- NCT05005559
- Testing
- SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant
- Where
- Iran
- Volunteers
- 16,876 people, healthy volunteers welcome
- Sponsor
- Cinnagen
COVID-19, Coronavirus Disease 2019
SARS-CoV-2 Nucleic Acid Detection Kit Clinical Performance Study
SARS-CoV-2 Nucleic Acid Detection Kit is an In Vitro Diagnostic (IVD) medical device intended for RNA detection of SARS-CoV-2 in human specimens using multiplex real-time polymerase chain reaction (RT-PCR) technology.
- Conditions
- COVID-19, Coronavirus Disease 2019, COVID-19 Pandemic, Diagnoses Disease
- Trial name
- CPS CW008 (NCT05492227)
- Testing
- Left-overs
- Where
- Spain
- Volunteers
- 607 people, healthy volunteers welcome
- Sponsor
- TransGen Biotech Co., LTD
COVID-19 SARS-CoV-2 Infection
A Phase III Clinical Trial to Evaluate the Efficacy and Safety of SCTV01E in Healthy People
The objective of this study is to evaluate the effectiveness of SCTV01E in healthy people
- Trial name
- NCT05683561
- Testing
- CoronaVac, SCTV01E
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
Coronavirus
Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2（COVID-19） Phase I Clinical Trial (3~17 Years Old)
Popular topic: Phase I clinical trial of recombinant new coronavirus vaccine (CHO cell) (3~17 years old) Research purpose:Main purpose:To evaluate the safety and tolerability of recombinant New Coronavirus vaccine (CHO cells) in…
- Trial name
- NCT04961359
- Testing
- Recombinant new coronavirus vaccine (CHO cell) group
- Where
- China
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
SARS-CoV-2 Infection, COVID-19
Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19
This was a phase IIa, double-blind, placebo-controlled, randomized trial, designed to compare the safety, tolerability, and antiviral activity of EIDD-2801 (molnupiravir) versus placebo as measured by SARS-CoV-2 viral RNA…
- Trial name
- NCT04405570
- Testing
- Molnupiravir 200 mg, Molnupiravir 400 mg, Molnupiravir 800 mg
- Where
- 10 sites in United States
- Volunteers
- 204 people
- Sponsor
- Ridgeback Biotherapeutics, LP
COVID-19
Open-label, Non-randomized, Non-comparative, Phase II Study of Safety and Immunogenicity of Combination of AZD1222 and rAd26-S for COVID-19 Prevention
The purpose of the study is to assess safety and immunogenicity of heterologous booster vaccine containing combination of AZD1222 and rAd26-S (one of components of Gam-COVID-Vac vaccine) in adult subjects aged ≥ 18 years old to…
- Trial name
- NCT04686773
- Testing
- AZD1222, rAd26-S
- Where
- Azerbaijan
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- R-Pharm
Identify the Viral Epitopes of Memory CD8 T Cells From Individuals That Have Recovered From SARS-CoV-2 Infection, Determine Which SARS-CoV-2 Proteins Are Frequently Recognized by T Cells in Patients With Varying HLA Types
Blood Collection Study From COVID-19 Convalescents Previously Hospitalized to Identify Immunogenic Viral Epitopes
The COVID-19 pandemic is a global emergency threatening to take millions of lives in the United States and around the world. There is no current vaccine strategy against COVID-19 infection caused by a novel coronavirus named…
- Trial name
- NCT04397900
- Where
- 2 sites in United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- TScan Therapeutics, Inc.
COVID-19, Coronavirus Infections
Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901e With E6020 Adjuvant
VBI-2901e is an investigational vaccine candidate that uses enveloped virus-like particles (eVLPs) to express the spike proteins of three coronaviruses: SARS-CoV-2 (the virus that causes COVID-19 disease), SARS-CoV-1 and…
- Trial name
- NCT05614245
- Testing
- VBI-2901e
- Where
- 4 sites in Canada
- Volunteers
- healthy volunteers welcome
- Sponsor
- VBI Vaccines Inc.
SARS-CoV-2 Infection
Nitric Oxide Nasal Spray (NONS) as Prevention for Treatment of Individuals at Risk of Exposure to COVID-19 Infection
A multicenter, randomized, double-blinded, placebo-controlled, phase 3 clinical efficacy study evaluating nitric oxide nasal spray (NONS) as prevention for treatment of individuals at risk of exposure to COVID-19 infection.
- Trial name
- NCT05109611
- Testing
- Nitric Oxide, Nasal spray with isotonic saline
- Where
- 6 sites in Canada, Sri Lanka
- Volunteers
- 1,389 people, healthy volunteers welcome
- Sponsor
- Sanotize Research and Development corp.
Coronavirus Disease 2019 (COVID-19)
Pharmacokinetics, Safety, and Tolerability of CSL760, an Intravenous Anti-SARS-CoV-2 Hyperimmune Globulin, in Healthy Adult Subjects
CSL760 is a human hyperimmune product of the purified gamma immunoglobulin (IgG) fraction of human plasma containing polyvalent neutralizing antibodies to SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2).
- Trial name
- NCT04638634
- Testing
- CSL760
- Where
- Australia
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- CSL Behring
SARS-CoV-2
Case Series Study to Detect SARS-CoV-2 in Semen of COVID-19 Patients
A descriptive, clinical series, single-centre, national, biomedical study to determine the presence of SARS-CoV-2 in sperm samples from positive PCR patients for COVID-19 and to evaluate the presence of the virus in the sperm…
- Trial name
- COVID-19CAST (NCT04717011)
- Testing
- PCR test
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- Igenomix
Covid19
Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults and Boost (VXA-CoV2-1.1-S) at 1 Year Post Initial Vaccination in Subset of Subjects
VXA-CoV2-1 is a non-replicating Ad5 vector adjuvanted oral tableted vaccine being developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection.
- Trial name
- NCT04563702
- Testing
- VXA-CoV2-1
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Vaxart
COVID-19
Expanded Access Program of Whole, Inactivated COVID-19 Vaccine COVAXIN™ (BBV152) in Adults Aged 18 Years and Older
This Expanded Access, Phase 3, open label study is intended to provide access to COVAXIN™ (BBV152) to individuals who are at risk or have predisposing conditions that can lead to complications with the current immunization…
- Trial name
- NCT05541289
- Testing
- BBV152
- Where
- United States
- Sponsor
- Ocugen
SARS-CoV-2 Infection
A Study to Assess the Efficacy and Safety of XC221 in Patients With COVID-19
The innovative drug XC221 100 mg tablet is designed for the treatment of COVID-19 (SARS-CoV-2 infection). A multicenter, adaptive, randomized, double-blind, placebo-controlled Phase III clinical study is aimed to assess the…
- Trial name
- NCT04487574
- Testing
- XC221
- Where
- 5 sites in Russia
- Volunteers
- 118 people
- Sponsor
- RSV Therapeutics LLC
COVID-19, SARS-COV-2 Infection
A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages ≥65 Years
The purpose of this study is to learn about the safety, tolerability, and immunogenicity of an updated vaccine against COVID-19.
- Trial name
- NCT07069309
- Testing
- BNT162b2 (2025/2026 recommended SARS-CoV-2 strain)
- Where
- 19 sites in United States
- Volunteers
- 774 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
COVID-19, Influenza A
Performance Evaluation of LumiraDx SARS-CoV-2, Flu A/B, and RSV Tests for COVID-19 Assessment
A Multicenter Study Conducted to Evaluate the Performance of the LumiraDx SARS-CoV-2 \& FLU A/B Test, and LumiraDx SARS-CoV-2 \& RSV Test at Point of Care Testing Sites.
- Conditions
- COVID-19, Influenza A, Influenza Type B, RSV Infection
- Trial name
- INSPIRE-2 (NCT05268939)
- Testing
- LumiraDx SARS-CoV-2 & Flu A/B test, LumiraDx SARS-CoV-2 & RSV test
- Where
- 8 sites in United States
- Volunteers
- 589 people
- Sponsor
- LumiraDx UK Limited
SARS-CoV-2, COVID-19
Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data
This study aims to use vaccination information from state vaccine registries linked with HealthVerity insurance claims for the following: to measure how effective the Pfizer-BioNTech vaccine is at preventing post-COVID…
- Conditions
- SARS-CoV-2, COVID-19, Post-Acute COVID-19 Syndrome
- Trial name
- NCT05876377
- Testing
- Pfizer-BioNTech COVID-19 mRNA vaccine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Pfizer
COVID-19
Phase I/II Clinical Trial of Recombinant Novel Coronavirus (COVID-19) Vaccine (Adenovirus Type 5 Vector) for Inhalation
This study is a randomized, double-blind, placebo-controlled I/II clinical trial, in order to evaluate the safety and immunogenicity of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) for Inhalation in adults 18…
- Trial name
- NCT04840992
- Testing
- Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) for Inhalation, Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
- Where
- China
- Volunteers
- 840 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Coronavirus Infection, Covid-19
Pilot Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19
This pilot study is being performed to assess the efficacy and safety of inhaled ensifentrine delivered via pMDI compared with a matching placebo in conjunction with standard of care treatments on recovery in patients…
- Conditions
- Coronavirus Infection, Covid-19, SARS-CoV-2
- Trial name
- NCT04527471
- Testing
- Ensifentrine Dose 1
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Verona Pharma Inc